Clinical trial · Interventional
The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma
The Role of Gadoxetate Enhanced Spectral Dual-Energy CT in Evaluating Hilar Cholangiocarcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this project is to evaluate the role of gadoxetate (Eovist®) enhanced dual-energy CT in better evaluating perihilar cholangiocarcinoma. This pilot project aims to address a long-term pitfall in the imaging of cholangiocarcinomas, by providing higher resolution delineation of these often infiltrative tumors on single-source, Dual-Energy Spectral Multi Detector CT (MDCT), capitalizing on improved spatial resolution achievable with MDCT compared to MRI and at the same time producing a non-invasive CT cholangiogram to aid in accurate diagnosis and treatment planning of cholangiocarcinoma, particularly, the hilar variety.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT scan | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CT imaging
- description
- Patients will undergo a standard of care Gadoxetate (Eovist) MRI for cholangiocarcinoma. Patients will then be immediately placed on the CT scanner. Patients will undergo a dual energy CT of the abdomen with no additional contrast.
- interventionNames
- Drug: CT scan
Primary outcomes (1)
- measure
- Number of Subjects Where Hilar Cholangiocarcinomas Could be Visualized Using Gadoxetate Disodium Enhanced Dual Energy CT
- timeFrame
- 24 hrs
- description
- CT scans were assessed for tumor visualization after use of Gadoxetate disodium
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subjects will be adult (age 19 or older) with suspected cholangiocarcinoma of the liver. 2. Subject must be able to provide a written informed consent. 3. Subject will be scheduled for gadoxetate contrast enhanced MRI scan of the liver (obtained as part of usual clinical practice). Exclusion Criteria: 1. Standard MRI safety screening criteria will be employed, and subject will be excluded if any contraindications to undergo MRI are met. 2. Subjects with metallic biliary stents or multiple peripancreatic surgical clips on abdominal MDCT will be excluded. 3. Subjects on hemodialysis or with glomerular filtration rate (GFR) less than 30 will be excluded. 4. Subjects will not be excluded on the basis of gender, race, ethnicity, or religion. 5. Subject may not be pregnant or lactating.
References
Publications (0)
Data not yet available